

Chemicals/Finland, November 14, 2023 Company update

CMD notes

Exel's CMD added details to its new strategy. Many important decisions are still to be worked out, but in our view the path for value creation is a lot clearer now.

Higher volumes and lower costs are to tame leverage ratio... Exel aims to keep NIBD/EBITDA below 3x by 2028; Exel has historically been around the ratio, but earnings weakness now pushed it to 4.8x even when the absolute level of debt was kept in check. The ratio is to improve next year as Exel sees growth in wind power but also within other industries as certain large integrated players, who have some insourced pultrusion volumes, are outsourcing business back to Exel. Margins have remained stable, despite the recent inflationary environment, and thus earnings have good potential to bounce back with higher volumes especially when Exel has achieved fixed cost reductions. Some portion of the EUR 20-25m projected financing need for the strategy period should be covered with internal cash flow when earnings rebound, yet there could be some larger outlays into key sites which would require a stronger balance sheet.

...while key asset focus may yet require external financing

Pultruded profiles' ability to insulate is one key quality driving volumes for buildings and transportation. China (wind power and transportation) is to be a volume site, whereas assets in Europe and the US are likely to be mostly tailored sites. Such sites help Exel integrate within the value chain (both engineering and post-processing services) and they should also feed orders to the volume business (such accounts need not be larger than EUR 4-5m). Exel expects the long-term split between tailored and volume sites at 60/40, whereas we would have expected the volume share to be a bit larger than that. Exel says post-processing services, which can e.g. help make final assembly easier, can be as valuable as the tailored composite volumes. Exel can also be quite selective within the tailored business, and we see value chain integration as a major part of the new strategy.

Our near-term estimates remain unchanged for now

Exel is likely to achieve a lot better results next year, but the rate of volume recovery is still uncertain while balance sheet could be stronger. The 9x EV/EBIT multiple, on our FY '24 estimates, isn't very high but in our view the uncertainties continue to limit upside potential. We retain our EUR 2.7 TP and HOLD rating.



■ BUY □ HOLD ■ SELL

KEY FIGU	RES									
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2021	134.4	3.7	2.8%	-6.2	0.14	57.0	1.0	34.9	-6.5	0.20
2022	137.0	3.0	2.2%	7.9	0.18	30.1	0.7	31.4	12.2	0.20
2023E	101.6	-4.8	-4.7%	-0.7	-0.68	-3.8	0.6	-13.3	-2.2	0.00
2024E	113.8	6.8	6.0%	1.7	0.27	9.6	0.5	9.1	5.5	0.15
2025E	121.7	8.5	7.0%	4.3	0.44	5.8	0.5	7.0	13.8	0.20
Market cap	o, EURm		31 G	earing 2023E,	0/0		5, %	35.0		
Net debt 2	023E, EURm		33 P	rice/book 2023	BE		1.5 CAGR	sales 2022-	25, %	-3.9
Enterprise	value, EURm		64 D	ividend yield 2	.023E, %		0.0 ROE 2	023E, %		-32.1
Total asset	s 2023E, EURn	n	94 Ta	ax rate 2023E,	0/0			-8.4		
Goodwill 2	023E, EURm		13 E	quity ratio 202	23E, %			0.0		



Chemicals/Finland, November 14, 2023 Company update

Estimates and valuation

Exel Composites	2019	2020	2021	Q1'22	Q2'22	Q3'22	Q4'22	2022	Q1'23	Q2'23	Q3'23	Q4'23e	2023e
Buildings and infrastructure	23.5	23.5	32.9	7.7	8.9	7.8	8.1	32.5	7.8	6.5	5.7	7.0	26.9
Equipment and other industries	18.6	19.5	23.4	7.4	5.9	5.6	4.3	23.1	5.6	5.0	4.0	3.8	18.4
Wind power	23.6	28.1	32.1	6.8	6.5	8.0	5.5	26.8	1.5	2.3	2.1	4.8	10.7
Machinery and electrical	14.4	15.5	17.6	4.3	5.3	5.0	5.2	19.7	4.6	4.1	3.4	4.6	16.7
Transportation	13.1	10.2	10.2	3.1	7.2	3.7	3.3	17.4	4.2	3.7	3.1	2.9	13.9
Defense	2.3	5.3	8.7	2.1	1.6	2.0	1.9	7.5	2.9	2.6	1.4	1.7	8.5
Telecommunications	8.2	6.5	9.5	2.8	2.8	1.7	2.6	10.0	2.2	1.3	8.0	2.1	6.4
Revenue	103.8	108.6	134.4	34.2	38.1	33.8	31.0	137.0	28.8	25.4	20.5	26.8	101.6
y/y change, %	7 %	5 %	24 %	10 %	14 %	1 %	-15 %	2 %	-16 %	-33 %	-39 %	-13 %	-26 %
Adjusted EBIT	7.2	9.7	6.0	2.2	3.1	1.8	0.9	8.0	0.0	0.1	-1.2	0.7	-0.4
EBIT	5.1	9.4	3.7	0.0	3.0	1.7	-1.7	3.0	-0.3	-0.2	-0.7	-3.6	-4.8
-margin, %	6.9 %	8.9 %	4.5 %	6.4 %	8.2 %	5.4 %	3.0 %	5.9 %	0.0 %	0.3 %	-5.9 %	2.6 %	-0.4 %
-margin (reported), %	4.9 %	8.7 %	2.8 %	0.1 %	7.9 %	5.0 %	-5.5 %	2.2 %	-1.0 %	-1.0 %	-3.2 %	-13.4 %	-4.7 %

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GROUP	MEUR	22	23	24	22	23	24	22	23	24
Hexagon Composites	421		14.8x	10.0x		28.3x	17.1x	-8.0 %	4.5 %	6.9 %
Hexcel	5115	19.0x	17.3x	14.5x	31.6x	26.9x	21.0x	11.4 %	12.8 %	14.8 %
Avient	2789	8.0x	9.3x	8.7x	11.7x	15.1x	13.1x	11.9 %	9.8 %	11.1 %
SGL Carbon	745	6.0x	7.4x	5.1x	9.9x	11.8x	7.8x	9.9 %	7.1 %	10.2 %
TPI Composites	85	13.1x		12.0x				-1.6 %	-9.0 %	-0.6 %
Gurit Holding	377	13.5x	11.6x	8.4x	22.6x	19.2x	12.3x	4.5 %	4.8 %	6.8 %
Peer Group Average	1589	11.9x	12.1x	9.8x	18.9x	20.3x	14.3x	4.7 %	5.0 %	8.2 %
Peer Group Median	583	13.1x	11.6x	9.4x	17.2x	19.2x	13.1x	7.2 %	6.0 %	8.5 %
Exel Composites (Evli est.)	31	9.3x	32.1x	4.8x	31.4x	-13.3x	9.1x	2.2 %	-4.7 %	6.0 %
Exel Composites prem./disc. to peer mea	lian	-29 %	177 %	-49 %	83 %	-169 %	-31%	-69 %	-179 %	-30 %

Source FactSet, Evli Research

Chemicals/Finland, November 14, 2023 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	2.59 PV of Free Cash Flow	55 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	8.79 PV of Horizon value	82 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	239.2 Unconsolidated equity	O Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	9.7 Marketable securities	17 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	8.0 Debt - dividend	-50 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	59.9 Value of stock	105 Nr of shares, Mn	11.9 Effective tax rate, %	21

DCF valuation, EURm	2022	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	Horizon
Net sales	137	102	114	122	128	130	133	136	138	141	143	145
Sales growth, %	2.0	-25.9	12.0	7.0	5.0	2.0	2.0	2.0	2.0	2.0	1.5	1.5
Operating income (EBIT)	3	-5	7	9	10	14	15	16	16	16	16	17
Operating income margin, %	2.2	-4.7	6.0	7.0	8.0	10.5	11.0	11.5	11.5	11.5	11.5	11.5
+ Depreciation+amort.	7	7	6	6	6	6	6	6	6	6	6	
EBITDA	10	2	13	15	16	19	20	21	22	22	22	
- Paid taxes	-1	-1	-2	-2	-3	-3	-4	-4	-4	-4	-4	
- Change in NWC	3	5	-2	-1	-1	0	0	0	0	0	0	
NWC / Sales, %	10.3	8.7	9.4	9.7	10.0	10.1	10.2	10.3	10.4	10.5	10.5	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-4	-4	- 5	-5	- 5	- 5	-6	-6	-6	-6	-6	
opCAPEX / Sales, %	3.5	4.6	5.2	4.9	4.7	4.4	4.4	4.4	4.4	4.4	4.3	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	8	2	4	6	7	10	11	11	11	12	12	173
= Discounted FCFF		2	3	5	6	7	7	7	6	6	6	82
= DFCF min WACC		2	3	5	6	7	7	7	7	6	6	92
= DFCF max WACC		2	3	5	6	7	7	7	6	6	5	73

Chemicals/Finland, November 14, 2023 Company update

INTERIM FIGURES

EVLI ESTIMATES, EURm	2022Q1	2022Q2	2022Q3	2022Q4	2022	2023Q1	2023Q2	2023Q3	2023Q4E	2023E	2024E	2025E
Net sales	34.2	38.1	33.8	31.0	137.0	28.8	25.4	20.5	26.8	101.6	113.8	121.7
EBITDA	1.8	4.8	3.6	0.0	10.1	1.5	1.5	1.1	-2.1	2.0	13.0	14.6
EBITDA margin (%)	5.2	12.5	10.5	0.0	7.4	5.3	5.7	5.6	-7.9	2.0	11.4	12.0
EBIT	0.0	3.0	1.7	-1.7	3.0	-0.3	-0.2	-0.7	-3.6	-4.8	6.8	8.5
EBIT margin (%)	0.1	7.9	5.0	-5.5	2.2	-1.0	-1.0	-3.2	-13.4	-4.7	6.0	7.0
Net financial items	0.5	1.9	1.6	-3.4	0.6	-1.2	-0.4	0.2	-0.3	-1.7	-1.6	-1.5
Pre-tax profit	0.5	4.9	3.3	-5.1	3.6	-1.5	-0.7	-0.4	-3.9	-6.5	5.2	7.0
Tax	-0.6	-0.9	-1.2	1.2	-1.5	-0.6	-0.2	-0.2	-0.5	-1.6	-2.0	-1.8
Tax rate (%)	111.4	19.3	35.6	24.3	40.4	-43.8	-36.3	-48.2	-12.8	-24.7	38.3	25.0
Net profit	-0.1	4.0	2.1	-3.9	2.1	-2.1	-0.9	-0.6	-4.4	-8.1	3.2	5.3
EPS	-0.01	0.33	0.18	-0.33	0.18	-0.18	-0.08	-0.05	-0.37	-0.68	0.27	0.44
EPS adjusted (diluted no. of shares)	-0.01	0.33	0.18	-0.33	0.18	-0.18	-0.08	-0.05	-0.37	-0.68	0.27	0.44
Dividend per share	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.00	0.00	0.00	0.15	0.20
SALES, EURm												
Exel Composites	34.2	38.1	33.8	31.0	137.0	28.8	25.4	20.5	26.8	101.6	113.8	121.7
Total	34.2	38.1	33.8	31.0	137.0	28.8	25.4	20.5	26.8	101.6	113.8	121.7
SALES GROWTH, Y/Y %												
Exel Composites	10.3	13.5	1.2	-15.1	2.0	-15.7	-33.3	-39.2	-13.5	-25.9	12.0	7.0
Total	10.3	13.5	1.2	- 15.1	2.0	-15.7	-33.3	-39.2	-13.5	-25.9	12.0	7.0
EBIT, EURm												
Exel Composites	0.0	3.0	1.7	-1.7	3.0	-0.3	-0.2	-0.7	-3.6	-4.8	6.8	8.5
Total	0.0	3.0	1.7	-1.7	3.0	-0.3	-0.2	-0.7	-3.6	-4.8	6.8	8.5
EBIT margin, %										*		
Exel Composites	0.1	7.9	5.0	-5.5	2.2	-1.0	-1.0	-3.2	-13.4	-4.7	6.0	7.0
Total	0.1	7.9	5.0	-5.5	2.2	-1.0	-1.0	-3.2	-13.4	-4.7	6.0	7.0

Chemicals/Finland, November 14, 2023 Company update

INCOME STATEMENT, EURm	2018	2019	2020	2021	2022	2023E	2024E	2025E
Sales	96.6	103.8	108.6	134.4	137.0	101.6	113.8	121.7
Sales growth (%)	11.9	7.5	4.6	23.7	2.0	-25.9	12.0	7.0
EBITDA	7.7	10.7	15.3	11.9	10.1	2.0	13.0	14.6
EBITDA margin (%)	8.0	10.3	14.1	8.9	7.4	2.0	11.4	12.0
Depreciation	-5.5	-5.6	-5.8	-8.2	-7.1	-6.8	-6.2	-6.1
EBITA	2.2	5.1	9.4	3.7	3.0	-4.8	6.8	8.5
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	2.2	5.1	9.4	3.7	3.0	-4.8	6.8	8.5
EBIT margin (%)	2.3	4.9	8.7	2.8	2.2	-4.7	6.0	7.0
Reported EBIT	2.2	5.1	9.4	3.7	3.0	-4.8	6.8	8.5
EBIT margin (reported) (%)	2.3	4.9	8.7	2.8	2.2	-4.7	6.0	7.0
Net financials	-0.5	-1.2	-2.3	0.4	0.6	-1.7	-1.6	-1.5
Pre-tax profit	1.7	3.9	7.1	4.2	3.6	-6.5	5.2	7.0
Taxes	-1.3	-1.5	-1.7	-2.5	-1.5	-1.6	-2.0	-1.8
Minority shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit	0.4	2.4	5.4	1.7	2.1	-8.1	3.2	5.3
Cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm								
Assets								
Fixed assets	21	23	30	34	31	29	29	29
Goodwill	13	13	13	13	13	13	13	13
Right of use assets	5	5	3	3	2	2	2	2
Inventory	15	17	16	24	23	17	19	21
Receivables	20	20	21	26	24	18	20	22
Liquid funds	5	7	12	16	17	13	14	15
Total assets	79	85	97	118	113	94	100	103
Liabilities	, 0	00	0,			0.		100
Shareholder's equity	26	26	29	31	30	20	23	27
Minority interest	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	3	4	2	2	1	2	2	2
Deferred taxes	0	0	0	0	1	1	1	1
Interest bearing debt	30	32	40	50	46	44	44	42
Non-interest bearing current liabilities	18	21	24	32	26	19	22	23
Other interest-free debt	2	2	2	3	9	9	9	9
Total liabilities	79	85	97	118	113	94	100	103
CASH FLOW, EURm								
+ EBITDA	8	11	15	12	10	2	13	15
- Net financial items	0	-1	-2	0	1	-2	-2	-1
- Taxes	-2	-2	-2	-3	-1	-2	-2	-2
- Increase in Net Working Capital	-4	1	3	-5	3	5	-2	-1
+/- Other	0	0	0	0	0	0	0	0
= Cash flow from operations	1	8	13	5	13	4	8	10
- Capex	-10	-8	-13	-11	-5	-5	-6	-6
- Acquisitions	0	0	-13	0	-3	-3	0	0
+ Divestments	0	0	0	0	0	0	0	0
= Free cash flow	-9	1	0	-6	8	-1	2	4
+/- New issues/buybacks	0	0	-1	3	-1	0	0	0
- Paid dividend	-4	-2	-1 -2	-2	-2	-2	0	-2
+/- Other	-4 9	-2 3	-2 7	-2 9	-2 -3	-2 -1	0	-2 -1
Change in cash	-3	3 2	5	4	-3 2	-1 -4	2	1
Change in Cash	-3	2	5	4	2	-4	۷	ı

Chemicals/Finland, November 14, 2023 Company update

KEY FIGURES	2019	2020	2021	2022	2023E	2024E	2025E
M-cap	78	88	94	64	31	31	31
Net debt (excl. convertibles)	29	30	36	30	33	31	29
Enterprise value	107	118	131	94	64	62	59
Sales	104	109	134	137	102	114	122
EBITDA	11	15	12	10	2	13	15
EBIT	5	9	4	3	-5	7	9
Pre-tax	4	7	4	4	-6	5	7
Earnings	2	5	2	2	-8	3	5
Equity book value (excl. minorities)	26	29	31	30	20	23	27
Valuation multiples							<u>.</u>
EV/sales	1.0	1.1	1.0	0.7	0.6	0.5	0.5
EV/EBITDA	10.0	7.7	10.9	9.3	32.1	4.8	4.1
EV/EBITA	21.0	12.5	34.9	31.4	-13.3	9.1	7.0
EV/EBIT	21.0	12.5	34.9	31.4	-13.3	9.1	7.0
EV/OCF	12.9	8.8	27.2	7.4	16.0	8.2	5.8
EV/FCFF	32.5	52.9	-26.0	12.4	38.4	17.4	10.0
P/FCFE	110.9	179.1	-15.3	8.2	-44.7	18.3	7.2
P/E	32.5	16.4	57.0	30.1	-3.8	9.6	5.8
P/B	3.0	3.1	3.0	2.1	1.5	1.3	1.2
Target EV/EBITDA	0.0	0.0	0.0	0.0	32.7	4.9	4.2
Target EV/EBIT	0.0	0.0	0.0	0.0	-13.6	9.3	7.1
Target EV/FCF	0.0	0.0	0.0	0.0	-94.3	37.6	14.3
Target P/B	0.0	0.0	0.0	0.0	1.6	1.4	1.2
Target P/E	0.0	0.0	0.0	0.0	-4.0	10.0	6.1
Per share measures							
Number of shares	11,897	11,897	11,897	11,897	11,897	11,897	11,897
Number of shares (diluted)	11,897	11,897	11,897	11,897	11,897	11,897	11,897
EPS	0.20	0.45	0.14	0.18	-0.68	0.27	0.44
Operating cash flow per share	0.70	1.12	0.40	1.06	0.33	0.64	0.86
Free cash flow per share	0.06	0.04	-0.52	0.66	-0.06	0.14	0.36
Book value per share	2.21	2.41	2.62	2.56	1.68	1.95	2.24
Dividend per share	0.18	0.20	0.20	0.20	0.00	0.15	0.20
Dividend payout ratio, %	89.2	44.3	143.7	110.9	0.0	55.3	45.1
Dividend yield, %	2.7	2.7	2.5	3.7	0.0	5.8	7.7
FCF yield, %	0.9	0.6	-6.5	12.2	-2.2	5.5	13.8
Efficiency measures							
ROE	9.2	19.5	5.5	7.0	-32.1	15.0	21.2
ROCE							
	8.6			4.0	-8.4	8.7	10.8
	8.6	14.4	5.1	4.0	-8.4	8.7	10.8
Financial ratios Inventories as % of sales	8.6			4.0	-8.4 17.1	17.1	17.1
Financial ratios		14.4	5.1				
Financial ratios Inventories as % of sales Receivables as % of sales	16.3 19.2	14.4 14.9 19.2	5.1 17.8 19.6	17.1 17.8	17.1 18.0	17.1 17.9	17.1 17.9
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales	16.3 19.2 20.2	14.4 14.9 19.2 22.0	5.1 17.8 19.6 23.8	17.1 17.8 19.1	17.1 18.0 19.1	17.1 17.9 19.1	17.1 17.9 19.1
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, %	16.3 19.2 20.2 14.1	14.4 14.9 19.2 22.0 11.2	5.1 17.8 19.6 23.8 12.7	17.1 17.8 19.1 10.3	17.1 18.0 19.1 8.7	17.1 17.9 19.1 9.4	17.1 17.9 19.1 9.7
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, %	16.3 19.2 20.2 14.1 7.3	14.4 14.9 19.2 22.0 11.2 11.9	5.1 17.8 19.6 23.8 12.7 8.2	17.1 17.8 19.1 10.3 3.5	17.1 18.0 19.1 8.7 4.6	17.1 17.9 19.1 9.4 5.2	17.1 17.9 19.1 9.7 4.9
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %	16.3 19.2 20.2 14.1 7.3 7.3	14.4 14.9 19.2 22.0 11.2 11.9	5.1 17.8 19.6 23.8 12.7 8.2 8.2	17.1 17.8 19.1 10.3 3.5 3.5	17.1 18.0 19.1 8.7 4.6 4.6	17.1 17.9 19.1 9.4 5.2 5.2	17.1 17.9 19.1 9.7 4.9 4.9
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	16.3 19.2 20.2 14.1 7.3 7.3 0.3	14.4 14.9 19.2 22.0 11.2 11.9 11.9	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4	17.1 17.8 19.1 10.3 3.5 3.5	17.1 18.0 19.1 8.7 4.6 4.6 0.8	17.1 17.9 19.1 9.4 5.2 5.2 0.3	17.1 17.9 19.1 9.7 4.9 4.9 0.4
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	16.3 19.2 20.2 14.1 7.3 7.3 0.3 2.7	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1 2.0	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4 3.0	17.1 17.8 19.1 10.3 3.5 3.5 0.8 2.9	17.1 18.0 19.1 8.7 4.6 4.6 0.8 16.5	17.1 17.9 19.1 9.4 5.2 5.2 0.3 2.4	17.1 17.9 19.1 9.7 4.9 4.9 0.4 2.0
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted Debt/equity, market-weighted	16.3 19.2 20.2 14.1 7.3 7.3 0.3 2.7 0.4	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1 2.0 0.5	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4 3.0 0.5	17.1 17.8 19.1 10.3 3.5 3.5 0.8 2.9 0.7	17.1 18.0 19.1 8.7 4.6 4.6 0.8 16.5	17.1 17.9 19.1 9.4 5.2 5.2 0.3 2.4 1.4	17.1 17.9 19.1 9.7 4.9 4.9 0.4 2.0
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	16.3 19.2 20.2 14.1 7.3 7.3 0.3 2.7	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1 2.0	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4 3.0	17.1 17.8 19.1 10.3 3.5 3.5 0.8 2.9	17.1 18.0 19.1 8.7 4.6 4.6 0.8 16.5	17.1 17.9 19.1 9.4 5.2 5.2 0.3 2.4	17.1 17.9 19.1 9.7 4.9 4.9 0.4 2.0

Chemicals/Finland, November 14, 2023 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	0/0
Erikoissijoitusrahasto Aktia Mikro Markka	762,984	1.976	6.4%
OP-Finland Small Firms Fund	752,993	1.950	6.3%
Ilmarinen Mutual Pension Insurance	496,547	1.286	4.2%
Phoebus Fund	420,000	1.088	3.5%
Säästöpankki Pienyhtiöt	288,710	0.748	2.4%
Sumato Oy	231,821	0.600	1.9%
Nelimarkka Heikki Antero	213,545	0.553	1.8%
Veritas Pension Insurance Company Ltd.	199,946	0.518	1.7%
Suutarinen Timo	160,000	0.414	1.3%
Säästöpankki Kotimaa	132,680	0.344	1.1%
Ten largest	3,659,226	9.477	31%
Residual	8,237,617	21.335	69%
Total	11,896,843	30.813	100%

EARNINGS CALENDAR	
February 16, 2024	FY 2023 Results
April 25, 2024	Q1 report
August 15, 2024	Q2 report
October 31, 2024	Q3 report
OTHER EVENTS	

CEO: Paul Sohlberg
CFO: Mikko Rummukainen
IR: Sanna Ahvenniemi

Mäkituvantie 5 01510 Vantaa Tel: +358 20 7541 200

Chemicals/Finland, November 14, 2023 Company update

DEFINITIONS

P/E	EPS
Price per share Earnings per share	Profit before extraord. items and taxes- income taxes + minority interest Number of shares
P/BV	DPS
Price per share Shareholders' equity + taxed provisions per share	Dividend for the financial period per share
Market cap	OCF (Operating cash flow)
Price per share * Number of shares	EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments
EV (Enterprise value)	FCF (Free cash flow)
Market cap + net debt + minority interest at market value – share of associated companies at market value	Operating cash flow – operative CAPEX – acquisitions + divestments
EV/Sales	FCF yield, %
Enterprise value Sales	Free cash flow Market cap
EV/EBITDA	Operative CAPEX/sales
Enterprise value Earnings before interest, tax, depreciation and amortization	Capital expenditure – divestments – acquisitions Sales
EV/EBIT	Net working capital
Enterprise value Operating profit	Current assets – current liabilities
Net debt	Capital employed/Share
Interest bearing debt – financial assets	Total assets – non-interest bearing debt Number of shares
Total assets	Gearing
Balance sheet total	<u>Net debt</u> Equity
Div yield, %	Debt/Equity, %
<u>Dividend per share</u> Price per share	Interest bearing debt Shareholders' equity + minority interest + taxed provisions
Payout ratio, %	Equity ratio, %
Total dividends Earnings before extraordinary items and taxes – income taxes + minority interest	Shareholders' equity + minority interest + taxed provisions Total assets – interest-free loans
ROCE, %	CAGR, %
Profit before extraordinary items + interest expenses+ other financial costs Balance sheet total - non-interest bearing debt (average)	Cumulative annual growth rate = Average growth per year
ROE, %	
Profit before extraordinary items and taxes – income taxes Shareholder's equity + minority interest + taxed provisions (average)	

Chemicals/Finland, November 14, 2023 Company update

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 11th of May 2020. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Plc. Production of the investment recommendation has been concluded on [14.11.2023, 9:15]. This report has been published on [14.11.2023, 9:35].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, November 14, 2023 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, November 14, 2023 Company update

Contact information SALES, TRADING AND RESEARCH

Equity, ETF and Derivatives Sales

 Joachim Dannberg
 +358 9 4766 9123

 Ari Laine
 +358 9 4766 9115

 Kimmo Lilja
 +358 9 4766 9130

Lauri Vehkaluoto (Head) +358 9 4766 9120
Pasi Väisänen +358 9 4766 9120
Antti Kässi +358 9 4766 9120
Miika Ronkanen +358 9 4766 9120

Structured Investments

 Heikki Savijoki
 +358 9 4766 9726

 Aki Lakkisto
 +358 9 4766 9123

Equity Research

Trading

Arttu Heikura +358 40 082 8098 Joonas Ilvonen +358 44 430 9071 Jerker Salokivi +358 9 4766 9149

Evli Investment Solutions

Johannes Asuja +358 9 4766 9205



EVLI PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000